ICD-116A62	CYCLOTHYMIC DISORDER Cyclothymic disorder
ICD-10F34.0	Cyclothymia
DSM-5-TRF34.0	Cyclothymic Disorder

1. Definition and nosology

Cyclothymic disorder (ICD-11: 6A62; DSM-5-TR: F34.0 Cyclothymic Disorder) — over a period of at least 2 years (1 year in children/adolescents) subthreshold chronic affective disorder characterized by persistent fluctuation between hypomanic and depressive symptoms. Does not meet criteria for full major depressive, manic, or hypomanic episodes.

2. History

• Kahlbaum K. (1882) — “cyclothymia” term.
• Kraepelin (1899) — a mild form of manic-depressive disorder.
• Akiskal H.S. (1977) — reconceptualization of cyclothymic temperament as a subthreshold stage of the bipolar spectrum.
• DSM-III (1980), DSM-5 (2013), ICD-11 (2019) — within the category of affective disorders.

3. Epidemiology

• Lifetime prevalence: 0.4–1% (DSM-5-TR; broad range, precise epidemiological data limited).
• Gender: approximately equal.
• Onset: adolescence and early adulthood.
• Type I or II conversion to bipolar: ~15–50% (Akiskal H.S. reviews).
• Comorbidity: anxiety, substance use, ADHD, borderline personality disorder.

4. Aetiology and pathogenesis

• Shared genetic load with the bipolar spectrum (Akiskal).
• Increased density of bipolar and major depressive disorder in family history.
• Neurobiological — monoaminergic and circadian dysregulation similar to bipolar disorder, but less pronounced.

5. Clinical features

• Multiple subthreshold hypomanic episodes — brief, low-intensity elevations in energy and mood.
• Multiple subthreshold depressive episodes — low-intensity depressive symptoms.
• “Stable period” less than 2 months.
• Mood changes over days or weeks; patient may explain themselves as ‘this is just my nature.’
• Interpersonal and occupational impairment is present, but not disruptive.

6. Diagnosis

6.1 Unified diagnostic criteria (DSM-5-TR · ICD-11)

A. At least 2 years (adults) / 1 year (children/adolescents) of numerous hypomanic and depressive subthreshold periods.

B. During this period, symptoms are present for ≥ half of the time, and symptom-free periods do not exceed 2 months.

C. Criteria for full major depressive, manic, or hypomanic episodes have never been met.

D. Not better explained by schizoaffective, schizophrenia or other psychotic disorder.

E. Exclusion of substance or medical condition.

F. Significant distress or functional impairment.

6.2 Diagnostic algorithm

1. Clinical interview (mood diary recommended for 4–6 weeks — documentation of patient's own patterns).
2. SCID-5, MDQ, HCL-32.
3. Comorbidity and family history assessment.
4. Medical and laboratory (thyroid absolute).

6.3 Differential diagnosis

7. Examination and assessment

• Mood diary.
• MDQ, HCL-32, YMRS, HAM-D.
• Thyroid function.

8. Treatment

1. Psychotherapy first line — CBT, IPSRT, psychoeducation, behavioral activation, circadian rhythm management.
2. Pharmacotherapy — evidence base is limited:
   • Lithium or valproate — considered adequate in the context of bipolar spectrum.
   • Lamotrigine — when depressive component is dominant.
   • Atypical antipsychotic (quetiapine) — in moderate-severe cases.
3. Antidepressant alone — risk of manic switch and rapid cycling; contraindicated.
4. Stress management and maintenance of social-circadian rhythm — important.
5. Monitoring for conversion to bipolar disorder — more frequent monitoring if family history and clinical markers present.

Source-specific specifications

• NICE CG185, CANMAT 2018 — separate algorithm for cyclothymic disorder is limited; bipolar spectrum principles apply; psychotherapy first-line.

Treatment methods

1. Interpersonal and Social Rhythm Therapy (IPSRT) - Frank (Frank E.) — Circadian rhythm and interpersonal stress management.
2. CBT for bipolar spectrum — Psychoeducation, behavioral activation, relapse markers.
3. Mood diary — Patient's documentation of own mood changes — diagnostic and therapeutic tool.
4. Lithium and lamotrigine — Pharmacotherapy of bipolar spectrum adequate.

9. Prognosis

• Chronic; spontaneous remission is rare.
• Risk of conversion to Bipolar Type I/II — annual clinical assessment.
• Comorbid substance use and BPD risk factors.
• Functional level improves with adequate treatment.

10. Myths and misconceptions

Myth 1: “Cyclothymic temperament is a normal personality trait, does not require treatment”

Clinical logic: cyclothymic temperament when it is a normal variant has no functional impairment; clinical diagnosis requires functional impairment. However, many patients have explained it as a ‘creative nature’ for years and do not seek intervention, while quality of life deteriorates.

Myth 2: “Cyclothymic disorder will not convert to bipolar”

Evidence: Akiskal — 15–50% conversion to bipolar Type I or II; higher risk if family history.

Myth 3: “Antidepressant alone manages all mood changes”

Evidence: Manic switching and rapid cycling risk; required concomitant with mood stabilizer.

Myth 4: “A cyclothymic patient will lose their creativity due to treatment”

Evidence: appropriate treatment (psychotherapy + mood stabilizer) helps preserve and enhance creativity (stabilized activity); romanticized ‘duality’ explanation leads to avoidance of intervention.

Myth 5: “Herbal preparations or diet cure cyclothymic disorder”

Evidence: St John's Wort risk of manic switch; omega-3 mild adjunct, not primary treatment.

11. Sources

1. WHO. ICD-11. 6A62 Cyclothymic disorder. 2024.
2. APA. DSM-5-TR. 2022.
3. NICE CG185. 2014/2020.
4. Yatham L.N. et al. CANMAT/ISBD 2018. Bipolar Disord 2018;20(2):97–170.
5. Akiskal H.S., Khani M.K., Scott-Strauss A. Cyclothymic temperamental disorders. Psychiatr Clin North Am 1979;2(3):527–554.
6. Frank E., Kupfer D.J., Thase M.E. et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005;62(9):996–1004.